欧盟EMA药品数据库(European Medicines Agency Authorisation of Medicines DataBase)
商品名称Tenkasi (previously Orbactiv)
适用类别Human
治疗领域Soft Tissue Infections;Skin Diseases, Bacterial
通用名/非专利名称oritavancin
活性成分oritavancin (diphosphate)
产品号EMEA/H/C/003785
患者安全信息No
许可状态Authorised
ATC编码J01XA05
是否额外监管No
是否仿制药或hybrid药物No
是否生物类似药No
是否附条件批准No
是否特殊情形No
是否加速审评No
是否罕用药No
上市许可日期2015/03/19
上市许可开发者/申请人/持有人Menarini International Operations Luxembourg S.A.
人用药物治疗学分组Antibacterials for systemic use
兽用药物治疗学分组
欧盟委员会决定日期2024/11/19
修订号16
治疗适应症Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients aged 3 months and older (see sections 4.2, 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
适用物种
兽用药物ATC编码
首次发布日期2018/06/25
最后更新日期2024/11/20
产品说明书https://www.ema.europa.eu/en/documents/product-information/tenkasi-previously-orbactiv-epar-product-information_en.pdf
公共评估报告https://www.ema.europa.eu/en/medicines/human/EPAR/tenkasi
©2006-2025 DrugFuture->European Medicines Agency Authorisation of Medicines DataBase